Namilumab

DRUG7 trials

Sponsors

Kinevant Sciences GmbH, Takeda, Izana Bioscience Ltd.

Conditions

Axial SpondyloarthritisPlaque PsoriasisRheumatoid ArthritisSarcoidosis, CardiacSarcoidosis, Pulmonarychronic pulmonary sarcoidosis

Phase 2

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

CompletedNCT02129777

TakedaPlaque Psoriasis

Start: 2014-06-30End: 2016-02-29Updated: 2017-04-07

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

CompletedNCT02379091

TakedaRheumatoid Arthritis

Start: 2014-12-17End: 2016-12-05Updated: 2018-09-14

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

TerminatedNCT02393378

TakedaRheumatoid Arthritis

Start: 2015-04-08End: 2016-11-16Updated: 2019-02-05

Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis

CompletedNCT03622658

Izana Bioscience Ltd.Axial Spondyloarthritis

Start: 2018-09-06End: 2020-02-04Updated: 2022-03-08

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

TerminatedNCT05314517

Kinevant Sciences GmbHSarcoidosis, Pulmonary

Start: 2022-08-31End: 2025-04-09Updated: 2025-09-12

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

TerminatedNCT05351554

Kinevant Sciences GmbHSarcoidosis, Cardiac

Start: 2022-08-23End: 2022-12-13Updated: 2025-04-17

A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis

CompletedCTIS2024-511115-25-00

Kinevant Sciences GmbHchronic pulmonary sarcoidosis

Start: 2022-11-21End: 2025-03-31Target: 33Updated: 2024-12-05

Related Papers

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study

European Respiratory Journal2026-03-12

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.

2024-06-258 citations

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.

2019-04-1868 citations

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.

2018-11-0231 citations

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Arthritis Research & Therapy2017-03-0835 citations